DIRS.INFO The most relevant business & tech news

☆ Supreme Court Allows $2.4 Billion Boy Scouts Sex Abuse Deal to Go Forward
▼ + stars: | 2024-02-22 | by ( Abbie Vansickle | More About Abbie Vansickle | ) www.nytimes.com time to read: 1 min

The Supreme Court cleared the way on Thursday for a $2.4 billion plan to settle sex abuse lawsuits against the Boy Scouts of America to go forward. The court’s brief, unsigned order gave no reasons, which is typical for emergency applications. There were no public dissents. A group of victims had asked the court to pause the plan as the justices consider an opioid settlement against Purdue Pharma, the manufacturer of OxyContin, and the members of the wealthy Sackler family who owned it, because that deal raised similar issues. Like the Purdue Pharma deal, the Boy Scouts agreement was settled in bankruptcy court using a contentious mechanism that insulates a third party from future lawsuits even without requiring that party to declare bankruptcy.

Persons: Sackler Organizations: Boy Scouts of, Purdue Pharma, Boy Scouts Locations: Boy Scouts of America

☆ Pharma stocks have quietly outperformed. Here’s one way to play the space
▼ + stars: | 2024-02-20 | by ( Katie Stockton | ) www.cnbc.com time to read: +6 min

— Katie Stockton with Will Tamplin Access research from Fairlead Strategies for free here . Fairlead Strategies Disclaimer: This communication has been prepared by Fairlead Strategies LLC ("Fairlead Strategies") for informational purposes only. Securities, investment products, other financial products or strategies discussed herein may not be suitable for all investors. The recipient of this information must make its own independent decisions regarding any securities, investment products or other financial products mentioned herein. This material is not to be reproduced or redistributed absent the written consent of Fairlead Strategies.

Persons: Eli Lilly, Katie Stockton Organizations: U.S . Pharmaceuticals, IHE, Fairlead, CNBC Pro, Securities Locations: U.S

☆ These are the only 2 ETFs that made money every year for the past decade
▼ + stars: | 2024-02-19 | by ( Ganesh Rao | ) www.cnbc.com time to read: +4 min

Two funds investing in defensive stocks are the only exchange-traded funds in the world that had a positive return every year over the past decade, CNBC Pro research has found. The two funds stood out among 8,300 equity ETFs worldwide screened by CNBC Pro using FactSet data. Over that period, the ETF more than doubled investors' money, with a cumulative total price gain of 118%. While the MSCI Healthcare index, valued in euros, dipped slightly into negative territory in 2016, 2020 and 2022, the Amundi ETF's total returns have remained positive because of the weakness in the pound sterling. However, Tabet also pointed out that the health-care sector, especially European pharma, tends to underperform in election years.

Persons: Joakim Tabet, Kepler, Tabet, Vincent Denoiseux, David Evans, Evans, Kepler Cheuvreux Organizations: CNBC, Healthcare UCITS, London Stock Exchange, TSX, Consumer Staples, CNBC Pro, Outlook Novo Nordisk, Novo Nordisk's, pharma, European pharma Locations: Canadian, Europe, Danish, Novo, U.S

☆ 'This is the mental health moment': Innovation and M&A are helping to boost these stocks to new heights
▼ + stars: | 2024-02-19 | by ( Michelle Fox | ) www.cnbc.com time to read: +14 min

There's been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Attention to a long-time crisis The mental health crisis is nothing new. However, there has also been a growing awareness and acceptance of mental health illnesses over the past decade, said Canaccord Genuity analyst Richard Close. "There's been recognition that mental health has a significant impact on a person's overall health," he said. "This is the mental health moment," said Dr. Ken Duckworth, NAMI's chief medical officer and author of "You Are Not Alone: The NAMI Guide to Mental Health."

Persons: There's, Covid, Peter Micca, AbbVie, Emraclidine, Myers Squibb, Karuna, Marc Goodman, Canaccord, Richard Close, MacKenzie Scott, Ken Duckworth, NAMI, Deloitte's Micca, William Blair, Myles Minter, Minter, Auvelity, Leerink's Goodman, Ashwani Verma, Verma, Goodman, BioHaven, Cerevel, Neumora, tardive, David Song, BetterHelp, psychedelics Johnson, Johnson, Spravato, Blair's Minter, Axsome, Micca, Michael Bloom Organizations: Institute for Health Metrics, Deloitte, Cerevel Therapeutics, Karuna Therapeutics, Bristol Myers, Leerink Partners, Centers for Disease Control, National Alliance, Mental, Mental Health, Wall Street, Therapeutics, Neumora Therapeutics, UBS, Karuna, Cellular Therapies, Xenon Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals, Tema Neuroscience, Axsome Therapeutics, Acadia Healthcare, BetterHelp, CNBC, pharma, Cellular Locations: Covid, Bristol, XEN1101, Acadia, Tema

☆ Morgan Stanley ponders if Eli Lilly could be the first $1 trillion pharma stock on weight loss boom
▼ + stars: | 2024-02-16 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +3 min

On Friday, Flynn raised his price target on Lilly shares to $950 from $805. With Lilly's stock closing Thursday at $757.78, the target suggests 25% more upside ahead. LLY 1Y mountain Eli Lilly shares over the past year. "LLY is establishing high barriers to entry in the diabesity market," Flynn said, adding that this is what contributes to its higher valuation. Phase 3 data is expected on orforglipron in 2025, which Flynn sees as a catalyst for the stock to go higher.

Persons: Eli Lilly, Morgan Stanley, Terence Flynn, Flynn, Lilly, Mounjaro, — CNBC's Michael Bloom Organizations: Novo Nordisk Locations: diabesity

☆ Trump May Face Harsh Punishment Thanks to a Mighty New York Law
▼ + stars: | 2024-02-16 | by ( Ben Protess | Jonah E. Bromwich | ) www.nytimes.com time to read: +1 min

That might seem steep in a case with no victim calling for redress and no star witness pointing the finger at Mr. Trump. But a little-known 70-year-old law made the punishment possible. The law, often referred to by its shorthand, 63(12), which stems from its place in New York’s rule book, is a regulatory bazooka for the state’s attorney general, Letitia James. In the Trump case, Ms. James accused the former president of inflating his net worth to obtain favorable loans and other financial benefits. Mr. Trump, she argued, defrauded his lenders.

Persons: Donald J, Trump, Letitia James, Martin Shkreli, James Organizations: Exxon Mobil, pharma Locations: New York, New

☆ Here are Friday's biggest analyst calls: Nvidia, Nike, Tesla, Coinbase, Arm, Meta, Eli Lilly, UPS, Carvana & more
▼ + stars: | 2024-02-16 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Here are Friday's biggest calls on Wall Street: Bank of America reiterates Meta as buy Bank of America said it's bullish on Meta adding the Broadcom CEO to its board of directors. Bank of America reiterates Nvidia as buy Bank of America said it's standing by the stock heading into earnings next week but that a pullback is possible. Baird upgrades UPS to outperform from neutral Baird said in its upgrade of UPS that the risk/reward is too attractive to ignore. Bank of America downgrades Dropbox to underperform from buy Bank of America said the "bull thesis has played out" for the data storage company. Bank of America upgrades Cellebrite to buy from neutral Bank of America said it sees business trends stabilizing for the digital intelligence company.

Persons: it's, Hock Tan, NVDA, Goldman Sachs, Goldman, TD Cowen, Grosvenor, KBW, TTD, Baird, Wells, Tommy Hilfiger, Tommy, Raymond James downgrades Carvana, Raymond James, Wayfair, Oppenheimer, Morgan Stanley, Tesla, Guggenheim, SunPower, Jefferies, Eli Lilly, Roku Organizations: Bank of America, Meta, Broadcom, " Bank of America, Nvidia, Informatica, BMO, Trade, Google, U.S, UPS, JPMorgan, Daiwa, CY2025, UBS, Newell Brands, RBC, Nike, of America, Barclays, Netflix, JPMorgan downgrades Bloom Energy, BE, Pharma Locations: CY24, CY2024, Wayfair, U.S

☆ Pharma and rideshare providers are among most overbought S&P 500 stocks this week
▼ + stars: | 2024-02-16 | by ( Alex Harring | ) www.cnbc.com time to read: +5 min

Despite the market's lack of direction this week, investors nonetheless poured into some specific stocks, pushing them into overbought territory. The RSI, which measures the magnitude and speed of price moves, is a popular yardstick used to evaluate whether shares are overbought or oversold. A stock with a 14-day RSI above 70 is considered overbought, signaling a possible selling opportunity. Biogen is another stock on the list that took a sizable drop this week, with shares tumbling more than 7%. But Wall Street anticipates a turnaround, with the consensus price target reflecting the potential for upside of more than 38%, according to FactSet.

Persons: Eli Lilly, Tesla, Morgan Stanley, Terence Flynn, FactSet, Uber, Stephen Bersey, Bersey Organizations: Dow Jones, Nasdaq, Federal Reserve, CNBC, RSI, pharma, Traders, Uber, Technologies, HSBC Locations: Thursday's, Biogen

UBS hiked its price target on Nvidia , citing an attractive valuation and strong demand for its chips. The firm upgraded shares to overweight from neutral and upped its target price by $17 to $68, which implies 24.3% potential upside. He upgraded shares to buy from neutral and increased his price target from £17 to £21. — Pia Singh 5:47 a.m.: UBS hikes Nvidia price target UBS is getting even more bullish on Nvidia ahead of the chipmaker's fiscal fourth-quarter earnings report. Despite the price target increase, Nvidia shares were down 1% in the premarket.

Persons: Riley Securities downgrades, Jeff Lick, Children's, Lick, — Pia Singh, Piper Sandler, Trimble, Clarke Jeffries, Mark Palmer, Palmer, Andrew Baum, Baum, GSK's, Timothy Arcuri, Arcuri, NVDA, Fred Imbert Organizations: CNBC, UBS, Nvidia, Citi, GSK, Riley Securities, Children's, Investment, Block Locations: Lick, Monday's, C2H

☆ I moved to Germany for a free education 8 years ago. I struggled to fit in, but here are the biggest reasons I never left.
▼ + stars: | 2024-02-09 | by ( Adriana Stein | ) www.businessinsider.com time to read: +9 min

She also says she appreciates Germany's Turkish community, ease of travel, and food transparency. It describes the tight-knit Turkish community and their ability to come together and help one another, regardless of the location. Insurance provides coverage, rather than trying to get out of payments with vague loopholesIn Germany, insurance is basically a way of life. AdvertisementNo matter where I rent a car, I use my German insurance because it has absolutely stellar coverage. My German insurance covered everything and it was a really easy process to go through.

Persons: Adriana Stein, Stein, —, I've, I'm, they've, you've, didn't, Germany hasn't Organizations: Service, Family Ministry, Social, EU, Turkish, Insurance, pharma, Big Pharma Locations: Germany, Hamburg, Kindergeld, Europe, Oregon, Turkish, South Africa

☆ Vertex Pharma CEO Kewalramani sits down with Jim Cramer
▼ + stars: | 2024-02-08 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Vertex Pharma CEO Kewalramani sits down with Jim CramerVertex Pharma President and CEO Dr. Reshma Kewalramani joins 'Mad Money' host Jim Cramer to talk sickle cell gene therapy, cystic fibrosis treatments and more.

Persons: Kewalramani, Jim Cramer, Reshma Kewalramani Organizations: Vertex Pharma, Pharma

☆ Final Trades: West Pharma, Sonos, Thermo Fisher and TransDigm
▼ + stars: | 2024-02-07 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: West Pharma, Sonos, Thermo Fisher and TransDigmToday’s “Halftime Report” Investment Committee, Steve Weiss, Joe Terranova, Brian Belski and Karen Firestone give their top picks to watch for the second half.

Persons: Today’s, Steve Weiss, Joe Terranova, Brian Belski, Karen Firestone Organizations: West Pharma, Investment

☆ Wednesday analyst calls: JPMorgan downgrades New York Community Bancorp, Eli Lilly gets big boost
▼ + stars: | 2024-02-07 | by ( Pia Singh | ) www.cnbc.com time to read: +8 min

Troubled regional bank New York Community Bank faced a downgrade from JPMorgan, which said NYCB is facing a multitude of challenges. The firm upped its price target for the drug maker to $850, all the way from $200. Wells Fargo : Analyst Zachary Fadem kept his overweight rating and raised his target price by $200 to $2,800, implying 12.5% upside for shares. "After speaking to management, we confirmed these two executives had indeed left the company, wrote JPMorgan analyst Steven Alexopoulos. NXP's stock price is down 2.9% for the year, but still higher than 15% over the past 12 months.

Persons: Eli Lilly, Eric Gonzalez, Gonzalez, Wells, Zachary Fadem, Sara Senatore, Chipotle, — Pia Singh, JPMorgan downgrades, Steven Alexopoulos, Alexopoulos, John Melloy, Vivek Arya, Arya, Robyn Karnauskas, Karnauskas, Zepbound Organizations: CNBC, New York Community Bank, JPMorgan, Pharma, Truist Securities, Semiconductors, Bank of America, KeyBanc, Barclays, New York Community Bank JPMorgan, New, Community Bank, Financial Times, Bloomberg News, New York Community Bancorp, Battery Management Systems, Food and Drug Administration Locations: Wells Fargo, Tuesday's

Guidepost didn't immediately respond to an email asking whether Morris & Dickson remains a client. Neither the DEA or Morris & Dickson immediately responded to a request for comment. While Morris & Dickson has managed to stay open, several of the pharmacies it supplied have closed, had their licenses revoked by the DEA or have been criminally prosecuted. Yet Morris & Dickson never suspended any shipments to the pharmacy. Over three years, it filed just three suspicious order reports to the DEA – none of which resulted in shipments being suspended.

Persons: Anne Milgram, Morris, Charles Dorman, Milgram's, Louis Milione, Milione, Morris & Dickson, Guidepost didn't, Dickson, ”, Katherine Pfaff, Judge Dorman, Wilkinson, Keith Wilkinson laundered, ___ Goodman Organizations: U.S . Drug, Morris, Dickson Co, Associated Press, AP, DEA, Morris & Dickson, Purdue Pharma, Guidepost Solutions, Morris &, Wilkinson Family Locations: Shreveport, La, New York, Morris, New Orleans, Miami, Mustian, Investigative@ap.org

☆ Tuesday, Feb. 6, 2024: Cramer breaks down why this pharma holding is surging after earnings
▼ + stars: | 2024-02-06 | by ( ) www.cnbc.com time to read: 1 min

Tuesday, Feb. 6, 2024: Cramer breaks down why this pharma holding is surging after earningsJim and Jeff discuss the strong quarter for this pharmaceutical stock. They also talk about the positive earnings on this Club shorted healthcare stock. Finally, they discuss Club stocks that may be interesting buys in the future.

Persons: Cramer, Jim, Jeff

☆ Startup funding is falling in most major cities. So why is Boston pulling ahead?
▼ + stars: | 2024-02-05 | by ( Melia Russell | Rebecca Torrence | ) www.businessinsider.com time to read: +8 min

AdvertisementThe Bay Area took the lion's share of capital raised on Carta in 2023, followed by Boston, then New York. AdvertisementAccording to Carta data, select metro areas saw the total early-stage funding raised decline by at least a third from 2022 to 2023. Yet early-stage funding was only down 24% in Boston, however, the smallest decrease of the metro areas that Carta tracks. According to Carta data, about $2.6 billion of capital raised in biotech flowed to Boston startups last year. Beyond biotechThe Carta data shows Boston also had strong showings across investment in software-as-a-service and hardware.

Persons: —, Zach Weinberg, Roche, Carta, Founders, that's, Rudina Seseri, Seseri, Peter Walker, Michael Greeley, Greeley, Mark Castleman, Castleman, Clement Cazalot, Cazalot, Walker Organizations: Service, Massachusetts Turnpike, Partners, Business, Carta, Boston, East Coast, Companies, Area, Flare Capital Partners, pharma, Intel Ignite, Glasswing Ventures, Founders, Machinery, Pritzker Group, Armory Square Ventures, Way Ventures, Klaviyo's, New York Stock Exchange Locations: Boston, New York City, East, Boston , Cambridge, Newton , Massachusetts, Newark, Jersey City , New Jersey, New York, San Francisco, Bay, France, Copley

☆ Obesity 'bolt-ons' likely to spur pharma M&A in 2024: Analyst
▼ + stars: | 2024-02-02 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailObesity 'bolt-ons' likely to spur pharma M&A in 2024: AnalystEmily Field, director and head of European pharmaceuticals equity research at Barclays, says the industry is likely to see an uptick in mergers and acquisitions in 2024, especially with smaller deals in the obesity drugs space.

Persons: Emily Field Organizations: pharma, Barclays

☆ 23andMe is low on cash and its stock is worth pennies. The CEO wants another chance
▼ + stars: | 2024-02-02 | by ( Nicole Goodkind | ) edition.cnn.com time to read: +8 min

New York CNN —Just three years ago, DNA testing company 23andMe was the golden child of Wall Street and Silicon Valley. In 2018, 23andMe agreed to a five-year exclusive drug development partnership with GSK (formerly GlaxoSmithKline). Genetic testing company 23andMe, once valued at $6 billion, is facing the possibility of delisting from NASDAQ. Justin Sullivan/Getty ImagesSo far, the partnership between GSK and 23andMe has produced more than 50 new drug targets. But drug discovery is a very long process and it can be anywhere from 10 to 15 years on average from target discovery to an FDA-approved drug.

Persons: New York CNN —, 23andMe, Anne Wojcicki, ” Wojcicki, “, Susan Wojcicki, Sergey Brin, Kyle Grillot, Wojcicki, they’ve, ”, we’re, “ We’ve, Steven Mah, TD Cowen, Mah, they’re, Justin Sullivan Organizations: New, New York CNN, Nasdaq, CNN, Stanford, Palo Alto High School, YouTube, Google, 23andMe Inc, Bloomberg, Time Magazine, P Biotech ETF, GSK, GlaxoSmithKline, NASDAQ, Big Pharma, it’s Locations: New York, Silicon Valley, Los Angeles , California, U.S, London, Sunnyvale , California, United States

☆ Tesla is one of the most oversold stocks in the S&P 500 and could be due for a bounce
▼ + stars: | 2024-02-02 | by ( Pia Singh | ) www.cnbc.com time to read: +5 min

Using the CNBC Pro Stock Screener tool, we screened for the most overbought and oversold names in the S & P 500 based on their 14-day relative strength index, or RSI. Stocks with a 14-day RSI greater than 70 are considered overbought, meaning they could be at risk of a pullback. Conversely, stocks with a reading lower than 30 typically means that they're oversold and possibly gearing up for a short-term bounce. Energy tech services provider Baker Hughes was one of the few oversold names that analysts have a buy rating on, according to CNBC's screen. Of the overbought names, Boston Scientific has the highest potential upside according to analysts surveyed by LSEG, at about 9.3%.

Persons: Jerome Powell, BYD, Robinson, Baker Hughes Organizations: Federal, Dow Jones, Nasdaq, CNBC, Stock, EV, Tesla, Transportation, Energy, United Parcel Service, Company, Pharma, Merck, Facebook, Boston Scientific, LSEG, Mastercard Locations: Minnesota, Thursday's

☆ An OxyContin advertiser will pay $350 million in the first-ever opioid marketing settlement
▼ + stars: | 2024-02-01 | by ( David Goldman | ) edition.cnn.com time to read: +3 min

Publicis, a French marketing company, agreed to pay $350 million within the next two months and will not take on any more opioid clients, according to New York Attorney General Letitia James. “For a decade, Publicis helped opioid manufacturers like Purdue Pharma convince doctors to overprescribe opioids, directly fueling the opioid crisis and causing the devastation of communities nationwide,” said James in a statement. For its alleged role in the opioid crisis, McKinsey in 2021 agreed to pay $573 million to states as part of multiple settlements. “The fight against the opioid crisis in the United States requires collaboration across industries, lawmakers, and communities, and we are committed to playing our part. Purdue Pharma first introduced the opioid drug OxyContin in the 1990s and promoted it as non-addictive.

Persons: Letitia James, Phil Weiser, Publicis, ”, James, ” Publicis, Sackler Organizations: New, New York CNN, Purdue Pharma’s, New York, Colorado, Purdue Pharma, McKinsey, Purdue, Centers for Disease Control, Biden, Sackler Locations: New York, French, United States

It is the first advertising company to reach a major settlement over the toll of opioids in the U.S. It faced a lawsuit in at least Massachusetts but settled with most states before they made court claims against it. James' office said the materials played up the abuse-deterrent properties of OxyContin and promoted increasing patients' doses. As part of the settlement, Publicis agreed to release internal documents detailing its work for Purdue and other companies that made opioids. The first began after OxyContin hit the market in 1996 and was linked mostly to prescription opioids, many of them generics.

Persons: Letitia James, Publicis, James, Bob Ferguson, Rosetta, ” Publicis, Sackler, OxyContin Organizations: Publicis, Publicis Groupe, New York, Purdue Pharma, Washington, Purdue, State Pharmacy, U.S, Supreme Locations: Paris, U.S, Massachusetts, Connecticut

☆ Teva Pharma CEO Richard Francis on Q4 earnings
▼ + stars: | 2024-01-31 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTeva Pharma CEO Richard Francis on Q4 earningsRichard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's recent divestiture, how easy it'll be to disentangle from part of its business, and more.

Persons: Richard Francis Organizations: Teva, Teva Pharmaceuticals

☆ GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost
▼ + stars: | 2024-01-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine. GSK in November had forecast 2023 sales for the shot Arexvy between £900 million, or $1.1 billion, and £1 billion, or $1.26 billion, following its strong launch in the U.S. The company's RSV shot in part drove the higher forecast. The vaccine has about 70% market share for RSV, Walmsley added on Wednesday. Meanwhile, biotech company Moderna hopes to launch its own RSV vaccine this year.

Persons: Emma Walmsley, Walmsley, Arexvy, That's, Pfizer's, Albert Bourla, Bourla Organizations: GlaxoSmithKline, Stevenage, GSK, U.S, Pfizer, U.S . Food, Drug Administration, Moderna Locations: Britain, British, U.S, Canada, Japan

Three names in the industry – Johnson & Johnson , Merck and Bristol Myers Squibb – face a pivotal few weeks ahead. They join Bristol Myers Squibb CEO Chris Boerner, who agreed to the panel's initial invitation to appear. But why is the committee targeting Merck, J&J and Bristol Myers Squibb in the first place? J&J, Merck and Bristol Myers Squib are all suing to halt the talks, which will establish new prices that will go into effect in 2026. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer.

Persons: Annika Kim Constantino, – Johnson, Sen, Bernie Sanders, Joaquin Duato, Robert Davis, Chris Boerner, Sanders, Eli Lilly's, Januvia, Bristol Myers, He's, Biden, Merck's, Myers, Eliquis, Mike Perrone, it's Organizations: CNBC.com, Johnson, Merck, Bristol Myers Squibb, Bristol Myers, Medicare, Bristol, CNBC, pharma Locations: U.S, drugmakers

☆ Danaher shares hit a 1-year high after earnings and we're increasing our price target
▼ + stars: | 2024-01-30 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

DHR 1Y mountain Danaher 1 year Shares of Danaher rose as much as 5% to a 52-week high of $245.40 each. Core sales, not shown on the table, were down 22.5%. Core sales were down 4% year over year as strength from academic and life science research customers was more than offset by weakness from pharma and biopharma customers. Core sales fell about the same as strength in clinical diagnostics, driven by Beckman Coulter Diagnostics was more than offset by lower respiratory revenue at Cepheid. In this photo illustration, Danaher Corporation logo is seen displayed on a smartphone and PC screen.

Persons: we've, Danaher, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Pavlo Gonchar Organizations: Revenue, LSEG, JPMorgan Healthcare, Sciences, Diagnostics, Biotechnology, Management, pharma, Beckman Coulter Diagnostics, CNBC, Getty Locations: Danaher, China, Biotechnology, North America, Europe, Asia, Pacific, Cepheid

Search resuls for: "PHARMA"

25 mentions found